While these results confirmed that strong DSB-inducing agents synergize with DNA-PK inhibition, we only observed in vivo tumor growth delay in the ZL-2201 and PLD in vivo combination study in A549 xenografts. The gene discussed is PRKDC; the disease is neoplasm.